PMID- 24443876
OWN - NLM
STAT- MEDLINE
DCOM- 20150309
LR  - 20220316
IS  - 1463-1326 (Electronic)
IS  - 1462-8902 (Linking)
VI  - 16
IP  - 7
DP  - 2014 Jul
TI  - Changes in weight loss-related quality of life among type 2 diabetes mellitus 
      patients treated with dapagliflozin.
PG  - 645-50
LID - 10.1111/dom.12263 [doi]
AB  - AIMS: This study evaluated change in health-related quality of life (HRQOL) 
      associated with ongoing weight change among patients with type 2 diabetes 
      mellitus (T2DM) treated with dapagliflozin, a highly selective sodium-glucose 
      cotransporter 2 (SGLT2) inhibitor that lowers blood glucose by increasing urinary 
      glucose excretion and is associated with body weight reductions. METHODS: 
      Patients with T2DM who had inadequate glycaemic control on metformin (MET) alone 
      were enrolled in a 24-week, double-blind, randomized, placebo-controlled study 
      with a 78-week extension to evaluate the effect of dapagliflozin + MET on body 
      weight. Patients also completed the Study to Help Improve Early evaluation and 
      management of risk factors Leading to Diabetes Weight Questionnaire-9 
      (SHIELD-WQ-9), a weight change-related HRQOL survey. Difference in proportions of 
      patients treated with dapagliflozin 10 mg + MET (n = 89) or placebo + MET 
      (n = 91) who reported improvement in HRQOL was analysed with Fisher's exact test. 
      RESULTS: Dapagliflozin patients had significantly greater weight loss than 
      placebo patients over 102 weeks (p < 0.05). This corresponded to a numerically 
      greater proportion of dapagliflozin-treated patients reporting ongoing weight 
      loss and associated improvements in most HRQOL domains at three different 
      evaluation points (weeks 24, 50 and 102) than placebo-treated patients. In a 
      post-hoc analysis among patients who reported ongoing weight loss regardless of 
      treatment arm, a significantly greater proportion of patients reporting weight 
      loss versus weight gain reported improvements in physical health, self-esteem and 
      overall HRQOL at weeks 24, 50 and 102. CONCLUSIONS: Dapagliflozin-induced weight 
      loss was associated with improvement in overall HRQOL. Overall, ongoing weight 
      loss was associated with improvements in several HRQOL domains compared with 
      weight gain.
CI  - (c) 2014 John Wiley & Sons Ltd.
FAU - Grandy, S
AU  - Grandy S
AD  - AstraZeneca LP, Wilmington, DE, USA.
FAU - Hashemi, M
AU  - Hashemi M
FAU - Langkilde, A-M
AU  - Langkilde AM
FAU - Parikh, S
AU  - Parikh S
FAU - Sjostrom, C D
AU  - Sjostrom CD
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20140209
PL  - England
TA  - Diabetes Obes Metab
JT  - Diabetes, obesity & metabolism
JID - 100883645
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Blood Glucose)
RN  - 0 (Glucosides)
RN  - 0 (Hypoglycemic Agents)
RN  - 1ULL0QJ8UC (dapagliflozin)
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Benzhydryl Compounds/*therapeutic use
MH  - Blood Glucose/drug effects
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Female
MH  - Glucosides/*therapeutic use
MH  - Health Status
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Male
MH  - Metformin/*therapeutic use
MH  - Middle Aged
MH  - *Quality of Life
MH  - Risk Assessment
MH  - Surveys and Questionnaires
MH  - Treatment Outcome
MH  - Weight Loss/*drug effects
OTO - NOTNLM
OT  - SGLT2 inhibitor
OT  - antidiabetic drug
OT  - clinical trial
OT  - diabetes mellitus
OT  - human adipose tissue
OT  - randomized trial
EDAT- 2014/01/22 06:00
MHDA- 2015/03/10 06:00
CRDT- 2014/01/22 06:00
PHST- 2013/11/04 00:00 [received]
PHST- 2014/01/13 00:00 [revised]
PHST- 2014/01/13 00:00 [accepted]
PHST- 2014/01/22 06:00 [entrez]
PHST- 2014/01/22 06:00 [pubmed]
PHST- 2015/03/10 06:00 [medline]
AID - 10.1111/dom.12263 [doi]
PST - ppublish
SO  - Diabetes Obes Metab. 2014 Jul;16(7):645-50. doi: 10.1111/dom.12263. Epub 2014 Feb 
      9.